AR112070A1 - Solución de infusión de levodopa - Google Patents
Solución de infusión de levodopaInfo
- Publication number
- AR112070A1 AR112070A1 ARP180101500A ARP180101500A AR112070A1 AR 112070 A1 AR112070 A1 AR 112070A1 AR P180101500 A ARP180101500 A AR P180101500A AR P180101500 A ARP180101500 A AR P180101500A AR 112070 A1 AR112070 A1 AR 112070A1
- Authority
- AR
- Argentina
- Prior art keywords
- solution
- aqueous
- levodopa
- cns
- standard solution
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 20
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 20
- 229960004502 levodopa Drugs 0.000 title abstract 20
- 239000003978 infusion fluid Substances 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 16
- 239000012086 standard solution Substances 0.000 abstract 16
- 239000003186 pharmaceutical solution Substances 0.000 abstract 13
- 239000000243 solution Substances 0.000 abstract 12
- 239000012062 aqueous buffer Substances 0.000 abstract 8
- 201000010099 disease Diseases 0.000 abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 7
- 239000007853 buffer solution Substances 0.000 abstract 4
- 239000000872 buffer Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- -1 at least 6 Chemical compound 0.000 abstract 2
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 239000008223 sterile water Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 229940125532 enzyme inhibitor Drugs 0.000 abstract 1
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una solución farmacéutica acuosa para usar en el tratamiento de enfermedades del sistema nervioso central (SNC), la solución que comprende al menos 5 mg/ml de levodopa disuelta, y que tiene un pH en el rango de 3,0 a 8,5. Dicha solución se proporciona mediante la mezcla a) una solución patrón acuosa que comprende levodopa, dicha solución patrón que tiene un pH menor de 2,8 a 25ºC y b) una solución buffer acuosa, para aumentar el pH de dicha solución patrón, dicha solución buffer que tiene un pH de al menos 4,0 a 25ºC. La solución farmacéutica acuosa se administra a un sujeto que sufre de una enfermedad del sistema nervioso central (SNC) inmediatamente después de mezclar la solución patrón acuosa y la solución buffer acuosa. Además, proporciona un kit para la administración de soluciones farmacéuticas acuosas a sujetos que sufren de enfermedades del sistema nervioso central (SNC). Reivindicación 1: Una solución farmacéutica acuosa para usar en el tratamiento de enfermedades del sistema nervioso central (SNC), la formulación farmacéutica acuosa que comprende, al menos 5 mg/ml de levodopa disuelta, y que tiene un pH en el rango de 3,0 a 8,5, donde dicha solución se proporciona mediante mezclado; a) la solución patrón acuosa que comprende levodopa, y dicha solución patrón que tiene un pH menor de 2,8 a 25ºC; y b) una solución buffer acuosa, para aumentar el pH de dicha solución patrón, que comprende al menos un componente buffer, dicha solución buffer que tiene un pH de al menos 4,0 a 25ºC, donde la solución farmacéutica acuosa se administra a un sujeto que sufre de una enfermedad del sistema nervioso central (SNC) dentro de 24 horas, tal como dentro de 16 horas, 12 horas, 6 horas, 4 horas, 2 horas, 1 hora, 30 minutos, 20 minutos, 10 minutos, 5 minutos o 1 minuto, a partir de la mezcla de la solución patrón acuosa y la solución buffer acuosa. Reivindicación 59: Un kit para proporcionar una solución farmacéutica acuosa, para usar en el tratamiento de enfermedades del sistema nervioso central (SNC), de acuerdo con cualquiera de las reivindicaciones precedentes, la solución farmacéutica acuosa que comprende al menos 5 mg/ml de levodopa disuelta, y que tiene un pH en el rango de 3,0 a 8,5, dicha kit que comprende; a) una solución patrón acuosa que comprende levodopa de acuerdo con cualquiera de las reivindicaciones precedentes, dicha solución patrón acuosa que tiene un pH menor de 2,8 a 25ºC, b) una solución buffer acuosa de acuerdo con cualquiera de las reivindicaciones precedentes, para aumentar el pH de dicha solución patrón acuosa, que comprende un buffer y que tiene un pH de al menos 4,0 a 25ºC; c) medio de mezcla (1) para mezclar dichas soluciones a) y b); y d) un medio de salida (2) para dicha solución mixta de la etapa c). Reivindicación 79: Un conjunto para proporcionar una solución farmacéutica acuosa, que comprende: I) una solución patrón acuosa, que tiene un pH menor de 2,8 a 25ºC que comprende; a) agua estéril, b) levodopa, c) al menos un inhibidor de enzima, d) al menos un ácido fisiológicamente aceptable, y e) al menos un estabilizante, y II) una solución buffer acuosa, que tiene un pH de al menos 4,0 a 25ºC, que comprende; f) agua estéril, g) al menos un componente buffer, y h) al menos un estabilizante y/o solubilizante. Reivindicación 103: Un método de preparación continua de una solución farmacéutica acuosa para usar en el tratamiento de enfermedades del sistema nervioso central (SNC), la solución farmacéutica acuosa que es adecuada para la administración enteral o parenteral continua, donde el método comprende: mezclar continuamente un flujo de una solución patrón que comprende levodopa, dicha solución patrón que tiene un pH menor de 2,8 a 25ºC y un flujo de una solución buffer acuosa, dicha solución buffer que tiene un pH de al menos 4,0 a 25ºC; y obtener continuamente de dicha mezcla un flujo continuo de una solución farmacéutica acuosa que comprende al menos 5 mg/ml de levodopa disuelta, tal como al menos 6, 7, 8, 9, 10, 15, ó 20 mg/ml de levodopa disuelta; con preferencia la concentración de levodopa que está en el rango de 5 a 20 mg/ml de levodopa disuelta, tal como en el rango 5 a 15 mg/ml o 5 a 10 mg/ml de levodopa disuelta. Reivindicación 135: Un método de tratamiento de enfermedades del sistema nervioso central (SNC) que comprende: mezclar continuamente un flujo de una solución patrón que comprende levodopa, dicha solución patrón que tiene un pH menor de 2,8 a 25ºC y un flujo de una solución buffer acuosa, dicha solución buffer que tiene un pH de al menos 4,0 a 25ºC; obtener continuamente de dicha mezcla un flujo continuo de una solución farmacéutica acuosa que comprende al menos 5 mg/ml de levodopa disuelta, tal como al menos 6, 7, 8, 9, 10, 15, ó 20 mg/ml de levodopa disuelta; con preferencia la concentración de levodopa que está en el rango de 5 a 20 mg/ml de levodopa disuelta, tal como en el rango 5 a 15 mg/ml o 5 a 10 mg/ml de levodopa disuelta; y administrar continuamente a un sujeto que sufre de una enfermedad del sistema nervioso central (SNC) la solución farmacéutica acuosa obtenida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750707 | 2017-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112070A1 true AR112070A1 (es) | 2019-09-18 |
Family
ID=62567647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101500A AR112070A1 (es) | 2017-06-05 | 2018-06-05 | Solución de infusión de levodopa |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11633353B2 (es) |
| EP (3) | EP3838263A1 (es) |
| JP (2) | JP7134228B2 (es) |
| KR (1) | KR102437003B1 (es) |
| CN (1) | CN110753538A (es) |
| AR (1) | AR112070A1 (es) |
| AU (1) | AU2018280745B2 (es) |
| BR (1) | BR112019025215A2 (es) |
| CA (1) | CA3065990A1 (es) |
| CY (1) | CY1124236T1 (es) |
| DK (1) | DK3634384T3 (es) |
| EA (1) | EA201992685A1 (es) |
| ES (1) | ES2866981T3 (es) |
| HR (1) | HRP20210599T1 (es) |
| HU (1) | HUE054268T2 (es) |
| IL (1) | IL271169B (es) |
| LT (1) | LT3634384T (es) |
| MX (1) | MX2019014675A (es) |
| PL (1) | PL3634384T3 (es) |
| PT (1) | PT3634384T (es) |
| RS (1) | RS61749B1 (es) |
| SI (1) | SI3634384T1 (es) |
| TW (1) | TW201902463A (es) |
| WO (1) | WO2018224501A1 (es) |
| ZA (1) | ZA201908027B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3634384T (lt) * | 2017-06-05 | 2021-07-12 | Dizlin Pharmaceuticals Ab | Levadopos infuzijos tirpalas |
| HUP2100456A1 (hu) * | 2021-12-28 | 2023-08-28 | Semmelweis Egyetem | Szemcsepp készítmény |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54105221A (en) | 1978-02-02 | 1979-08-18 | Sankyo Co Ltd | Preparation of stable concentrated dopa injection |
| SE512655C2 (sv) | 1993-11-17 | 2000-04-17 | Medmera Sweden Hb C O Nil Dizd | Infusionslösning för medicinskt bruk innehållande L-dopa |
| DE19757224A1 (de) | 1997-12-22 | 1999-07-01 | Bayer Ag | Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| CA2536175C (en) | 2003-08-29 | 2013-05-28 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| ES2360759T3 (es) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| DK2432454T3 (en) | 2009-05-19 | 2017-06-19 | Neuroderm Ltd | COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA DECARBOXYLASE INHIBITORS |
| AU2011101361A4 (en) | 2010-11-15 | 2011-12-15 | Andrew Lumsden | A prefilled syringe for administering buffered lignocaine |
| PL3326615T3 (pl) | 2010-11-15 | 2020-07-27 | Neuroderm Ltd | Ciągłe podawanie L-dopy, inhibitorów dekarboksylazy dopy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji |
| CN102755252A (zh) * | 2011-07-28 | 2012-10-31 | 辽宁海思科制药有限公司 | 一种新的包装氨基酸葡萄糖注射液的双室输液袋 |
| CN105209029A (zh) * | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| US10420888B2 (en) | 2013-09-03 | 2019-09-24 | Max Arocha | Double-chamber mixing syringe and method of use |
| LT3634384T (lt) * | 2017-06-05 | 2021-07-12 | Dizlin Pharmaceuticals Ab | Levadopos infuzijos tirpalas |
-
2018
- 2018-06-05 LT LTEP18730319.3T patent/LT3634384T/lt unknown
- 2018-06-05 BR BR112019025215-0A patent/BR112019025215A2/pt unknown
- 2018-06-05 EA EA201992685A patent/EA201992685A1/ru unknown
- 2018-06-05 SI SI201830257T patent/SI3634384T1/sl unknown
- 2018-06-05 CN CN201880037143.6A patent/CN110753538A/zh active Pending
- 2018-06-05 TW TW107119351A patent/TW201902463A/zh unknown
- 2018-06-05 PT PT187303193T patent/PT3634384T/pt unknown
- 2018-06-05 ES ES18730319T patent/ES2866981T3/es active Active
- 2018-06-05 EP EP21153018.3A patent/EP3838263A1/en active Pending
- 2018-06-05 AU AU2018280745A patent/AU2018280745B2/en active Active
- 2018-06-05 PL PL18730319T patent/PL3634384T3/pl unknown
- 2018-06-05 CA CA3065990A patent/CA3065990A1/en active Pending
- 2018-06-05 WO PCT/EP2018/064774 patent/WO2018224501A1/en active Search and Examination
- 2018-06-05 US US16/619,176 patent/US11633353B2/en active Active
- 2018-06-05 HU HUE18730319A patent/HUE054268T2/hu unknown
- 2018-06-05 EP EP18730319.3A patent/EP3634384B1/en active Active
- 2018-06-05 IL IL271169A patent/IL271169B/en unknown
- 2018-06-05 RS RS20210467A patent/RS61749B1/sr unknown
- 2018-06-05 JP JP2020516960A patent/JP7134228B2/ja active Active
- 2018-06-05 EP EP24183451.4A patent/EP4445953A2/en active Pending
- 2018-06-05 MX MX2019014675A patent/MX2019014675A/es unknown
- 2018-06-05 DK DK18730319.3T patent/DK3634384T3/da active
- 2018-06-05 AR ARP180101500A patent/AR112070A1/es unknown
- 2018-06-05 KR KR1020197037906A patent/KR102437003B1/ko active IP Right Grant
-
2019
- 2019-12-03 ZA ZA2019/08027A patent/ZA201908027B/en unknown
-
2021
- 2021-04-15 HR HRP20210599TT patent/HRP20210599T1/hr unknown
- 2021-04-23 CY CY20211100353T patent/CY1124236T1/el unknown
-
2022
- 2022-06-29 JP JP2022104764A patent/JP7437450B2/ja active Active
-
2023
- 2023-02-28 US US18/175,599 patent/US12048764B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112070A1 (es) | Solución de infusión de levodopa | |
| EP3964203A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| NO20084199L (no) | Formuleringer for modifisert frigjoring og fremgangsmater for behandling av inflammatorisk tarmsykdom | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2017121203A (ru) | НОВЫЕ ПОЛИМЕРНЫЕ hGH ПРОЛЕКАРСТВА | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| AU2020344820A1 (en) | Use of NMN for the prevention and/or treatment of pain, and corresponding compositions | |
| TW201713330A (zh) | 肌肉脂肪化抑制用組成物 | |
| RU2016116708A (ru) | Олигопептиды металлопротеиназ и их терапевтическое применение | |
| Paderni et al. | Controlled delivery of naltrexone by an intraoral device: in vivo study on human subjects | |
| WO2012044783A3 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| AR083393A1 (es) | Composicion farmaceutica liquida para el tratamiento y prevencion del dolor | |
| JP2022110125A (ja) | 炎症メディエーターのレベルを低減するための組成物及び方法 | |
| Xiao et al. | Cathepsin S in the spinal microglia facilitates morphine-induced antinociceptive tolerance in rats | |
| AR078290A1 (es) | Composicion farmaceutica. funcion del acido n-2-hidroxi-etil-piperazin-n`-2- etanosulfonico (hepes) en el control del dolor y en la prevencion de lesiones desmielinizantes. metodo para tratar dolor. | |
| RU2375066C2 (ru) | Способ профилактики ранних послеоперационных тромбоэмболических осложнений | |
| RU2580657C1 (ru) | Способ лечения больных риносинуситом | |
| JP2013126971A (ja) | 抗感冒剤 | |
| BR112012033695A2 (pt) | tratamento com l-metilfolato para distúrbios psiquiátricos ou neurológicos. | |
| BRPI0925000B8 (pt) | solução de n,n-diamino-difenil sulfona e seu uso terapêutico | |
| RU2007141393A (ru) | Способ лечения спастического и болевого синдромов у пациентов с последствиями позвоночно-спинномозговой травмы | |
| RU2417091C2 (ru) | Способ лечения артрозо-артритов | |
| JP2009539941A (ja) | Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤 |